Genfit S.A. (LON:0QT6)

Market Cap	243.67M
Revenue (ttm)	38.68M -43.9%
Net Income	-33.22M
EPS	-0.70
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	999
Average Volume	3,304
Open	5.67
Previous Close	5.70
Day's Range	5.63 - 5.67
52-Week Range	2.70 - 5.71
Beta	0.96
RSI	64.77
Earnings Date	Apr 2, 2026

About Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patien...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 188
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QT6

Financial Performance

Financial numbers in EUR